Kelley M Faber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8724270/publications.pdf Version: 2024-02-01



KELLEV M FARED

#	#	Article	IF	CITATIONS
1	L	The National Institute on Aging Lateâ€Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery. Alzheimer's and Dementia, 2022, 18, 1889-1897.	0.8	9
2	2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
ç	3	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
4	1	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. Journal of Clinical Medicine, 2021, 10, 1907.	2.4	15
Ę	5	Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS) genetic screening: Initial results. Alzheimer's and Dementia, 2021, 17, e056493.	0.8	0
e	5	ADSP followâ€up study: NCRAD biospecimens. Alzheimer's and Dementia, 2021, 17, e056242.	0.8	0
7	7	Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, e052495.	0.8	0
8	3	NCRAD Family Study and NIA‣OAD brain tissue: A NCRAD resource. Alzheimer's and Dementia, 2021, 17, e056284.	0.8	1
ç)	Establishing a centralized repository of human pluripotent stem cells for neurodegeneration research Alzheimer's and Dementia, 2021, 17 Suppl 3, e053911.	0.8	ο
1	10	ADRC GWAS supplement: An NCRAD initiative Alzheimer's and Dementia, 2021, 17 Suppl 3, e056176.	0.8	0
1	11	Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223.	0.8	23
1	12	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. Alzheimer's and Dementia, 2020, 16, e045482.	0.8	0
1	13	The Alzheimer's disease sequencing project–follow up study (ADSPâ€FUS): Increasing ethnic diversity in Alzheimer's genetics research with addition of potential new cohorts. Alzheimer's and Dementia, 2020, 16, e046400.	0.8	3
1	14	Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Clinical Epigenetics, 2020, 12, 84.	4.1	57
1	15	Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort. Journal of Alzheimer's Disease, 2019, 71, 33-43.	2.6	14
1	16	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
1	17	O4â€03â€01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA. Alzheimer's and Dementia, 2019, 15, P1234.	0.8	0
1	18	P1â€433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC <i>MAPT</i> MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.8	0

Kelley M Faber

#	Article	IF	CITATIONS
19	P1â€597: AMYLOID NEUROIMAGING AND GENETICS INITIATIVE: IMPLEMENTING DNA COLLECTION USING NOVEL CONSENTING APPROACHES FOR AN IDEAS ADDâ€ON STUDY. Alzheimer's and Dementia, 2018, 14, P566.	0.8	0
20	P1â€281: NONLINEAR Nâ€SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET. Alzheimer's and Dementia, 2018, 14, P390.	0.8	1
21	P1â€∎49: THE ALZHEIMER'S DISEASE SEQUENCING PROJECT (ADSP) DATA UPDATE 2018. Alzheimer's and Dementia, 2018, 14, P333.	0.8	0
22	O2â€14â€01: CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAM FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL. Alzheimer's and Dementia, 2018, 14, P656.	IILIAL 0.8	0
23	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
24	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA Neurology, 2016, 73, 1231.	9.0	49
25	Genetic variants associated with susceptibility to psychosis inÂlate-onset Alzheimer's disease families. Neurobiology of Aging, 2015, 36, 3116.e9-3116.e16.	3.1	14
26	Rarity of the Alzheimer Disease–Protective <i>APP</i> A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
27	A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy. JAMA Neurology, 2015, 72, 414.	9.0	37
28	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer's and Dementia, 2015, 11, 792-814.	0.8	241
29	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
30	Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families. JAMA Neurology, 2014, 71, 315.	9.0	48
31	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
32	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
33	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
34	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676